Eintrag weiter verarbeiten
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support
Gespeichert in:
| Zeitschriftentitel: | Blood Advances |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , |
| In: | Blood Advances, 4, 2020, 2, S. 327-355 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| author_facet |
Chou, Stella T. Alsawas, Mouaz Fasano, Ross M. Field, Joshua J. Hendrickson, Jeanne E. Howard, Jo Kameka, Michelle Kwiatkowski, Janet L. Pirenne, France Shi, Patricia A. Stowell, Sean R. Thein, Swee Lay Westhoff, Connie M. Wong, Trisha E. Akl, Elie A. Chou, Stella T. Alsawas, Mouaz Fasano, Ross M. Field, Joshua J. Hendrickson, Jeanne E. Howard, Jo Kameka, Michelle Kwiatkowski, Janet L. Pirenne, France Shi, Patricia A. Stowell, Sean R. Thein, Swee Lay Westhoff, Connie M. Wong, Trisha E. Akl, Elie A. |
|---|---|
| author |
Chou, Stella T. Alsawas, Mouaz Fasano, Ross M. Field, Joshua J. Hendrickson, Jeanne E. Howard, Jo Kameka, Michelle Kwiatkowski, Janet L. Pirenne, France Shi, Patricia A. Stowell, Sean R. Thein, Swee Lay Westhoff, Connie M. Wong, Trisha E. Akl, Elie A. |
| spellingShingle |
Chou, Stella T. Alsawas, Mouaz Fasano, Ross M. Field, Joshua J. Hendrickson, Jeanne E. Howard, Jo Kameka, Michelle Kwiatkowski, Janet L. Pirenne, France Shi, Patricia A. Stowell, Sean R. Thein, Swee Lay Westhoff, Connie M. Wong, Trisha E. Akl, Elie A. Blood Advances American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support Hematology |
| author_sort |
chou, stella t. |
| spelling |
Chou, Stella T. Alsawas, Mouaz Fasano, Ross M. Field, Joshua J. Hendrickson, Jeanne E. Howard, Jo Kameka, Michelle Kwiatkowski, Janet L. Pirenne, France Shi, Patricia A. Stowell, Sean R. Thein, Swee Lay Westhoff, Connie M. Wong, Trisha E. Akl, Elie A. 2473-9529 2473-9537 American Society of Hematology Hematology http://dx.doi.org/10.1182/bloodadvances.2019001143 <jats:sec><jats:title>Background:</jats:title><jats:p>Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention, and management of alloimmunization, delayed hemolytic transfusion reactions (DHTRs), and iron overload may improve outcomes.</jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p>Our objective was to develop evidence-based guidelines to support patients, clinicians, and other healthcare professionals in their decisions about transfusion support for SCD and the management of transfusion-related complications.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>The American Society of Hematology formed a multidisciplinary panel that was balanced to minimize bias from conflicts of interest and that included a patient representative. The panel prioritized clinical questions and outcomes. The Mayo Clinic Evidence-Based Practice Research Program supported the guideline development process. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to form recommendations, which were subject to public comment.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The panel developed 10 recommendations focused on red cell antigen typing and matching, indications, and mode of administration (simple vs red cell exchange), as well as screening, prevention, and management of alloimmunization, DHTRs, and iron overload.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>The majority of panel recommendations were conditional due to the paucity of direct, high-certainty evidence for outcomes of interest. Research priorities were identified, including prospective studies to understand the role of serologic vs genotypic red cell matching, the mechanism of HTRs resulting from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy for women, and the optimal treatment of transfusional iron overload in SCD.</jats:p></jats:sec> American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support Blood Advances |
| doi_str_mv |
10.1182/bloodadvances.2019001143 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZGFkdmFuY2VzLjIwMTkwMDExNDM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZGFkdmFuY2VzLjIwMTkwMDExNDM |
| institution |
DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 |
| imprint |
American Society of Hematology, 2020 |
| imprint_str_mv |
American Society of Hematology, 2020 |
| issn |
2473-9529 2473-9537 |
| issn_str_mv |
2473-9529 2473-9537 |
| language |
English |
| mega_collection |
American Society of Hematology (CrossRef) |
| match_str |
chou2020americansocietyofhematology2020guidelinesforsicklecelldiseasetransfusionsupport |
| publishDateSort |
2020 |
| publisher |
American Society of Hematology |
| recordtype |
ai |
| record_format |
ai |
| series |
Blood Advances |
| source_id |
49 |
| title |
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_unstemmed |
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_full |
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_fullStr |
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_full_unstemmed |
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_short |
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_sort |
american society of hematology 2020 guidelines for sickle cell disease: transfusion support |
| topic |
Hematology |
| url |
http://dx.doi.org/10.1182/bloodadvances.2019001143 |
| publishDate |
2020 |
| physical |
327-355 |
| description |
<jats:sec><jats:title>Background:</jats:title><jats:p>Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention, and management of alloimmunization, delayed hemolytic transfusion reactions (DHTRs), and iron overload may improve outcomes.</jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p>Our objective was to develop evidence-based guidelines to support patients, clinicians, and other healthcare professionals in their decisions about transfusion support for SCD and the management of transfusion-related complications.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>The American Society of Hematology formed a multidisciplinary panel that was balanced to minimize bias from conflicts of interest and that included a patient representative. The panel prioritized clinical questions and outcomes. The Mayo Clinic Evidence-Based Practice Research Program supported the guideline development process. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to form recommendations, which were subject to public comment.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The panel developed 10 recommendations focused on red cell antigen typing and matching, indications, and mode of administration (simple vs red cell exchange), as well as screening, prevention, and management of alloimmunization, DHTRs, and iron overload.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>The majority of panel recommendations were conditional due to the paucity of direct, high-certainty evidence for outcomes of interest. Research priorities were identified, including prospective studies to understand the role of serologic vs genotypic red cell matching, the mechanism of HTRs resulting from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy for women, and the optimal treatment of transfusional iron overload in SCD.</jats:p></jats:sec> |
| container_issue |
2 |
| container_start_page |
327 |
| container_title |
Blood Advances |
| container_volume |
4 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347421807738881 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:55:01.511Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=American+Society+of+Hematology+2020+guidelines+for+sickle+cell+disease%3A+transfusion+support&rft.date=2020-01-28&genre=article&issn=2473-9537&volume=4&issue=2&spage=327&epage=355&pages=327-355&jtitle=Blood+Advances&atitle=American+Society+of+Hematology+2020+guidelines+for+sickle+cell+disease%3A+transfusion+support&aulast=Akl&aufirst=Elie+A.&rft_id=info%3Adoi%2F10.1182%2Fbloodadvances.2019001143&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347421807738881 |
| author | Chou, Stella T., Alsawas, Mouaz, Fasano, Ross M., Field, Joshua J., Hendrickson, Jeanne E., Howard, Jo, Kameka, Michelle, Kwiatkowski, Janet L., Pirenne, France, Shi, Patricia A., Stowell, Sean R., Thein, Swee Lay, Westhoff, Connie M., Wong, Trisha E., Akl, Elie A. |
| author_facet | Chou, Stella T., Alsawas, Mouaz, Fasano, Ross M., Field, Joshua J., Hendrickson, Jeanne E., Howard, Jo, Kameka, Michelle, Kwiatkowski, Janet L., Pirenne, France, Shi, Patricia A., Stowell, Sean R., Thein, Swee Lay, Westhoff, Connie M., Wong, Trisha E., Akl, Elie A., Chou, Stella T., Alsawas, Mouaz, Fasano, Ross M., Field, Joshua J., Hendrickson, Jeanne E., Howard, Jo, Kameka, Michelle, Kwiatkowski, Janet L., Pirenne, France, Shi, Patricia A., Stowell, Sean R., Thein, Swee Lay, Westhoff, Connie M., Wong, Trisha E., Akl, Elie A. |
| author_sort | chou, stella t. |
| container_issue | 2 |
| container_start_page | 327 |
| container_title | Blood Advances |
| container_volume | 4 |
| description | <jats:sec><jats:title>Background:</jats:title><jats:p>Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention, and management of alloimmunization, delayed hemolytic transfusion reactions (DHTRs), and iron overload may improve outcomes.</jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p>Our objective was to develop evidence-based guidelines to support patients, clinicians, and other healthcare professionals in their decisions about transfusion support for SCD and the management of transfusion-related complications.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>The American Society of Hematology formed a multidisciplinary panel that was balanced to minimize bias from conflicts of interest and that included a patient representative. The panel prioritized clinical questions and outcomes. The Mayo Clinic Evidence-Based Practice Research Program supported the guideline development process. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to form recommendations, which were subject to public comment.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The panel developed 10 recommendations focused on red cell antigen typing and matching, indications, and mode of administration (simple vs red cell exchange), as well as screening, prevention, and management of alloimmunization, DHTRs, and iron overload.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>The majority of panel recommendations were conditional due to the paucity of direct, high-certainty evidence for outcomes of interest. Research priorities were identified, including prospective studies to understand the role of serologic vs genotypic red cell matching, the mechanism of HTRs resulting from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy for women, and the optimal treatment of transfusional iron overload in SCD.</jats:p></jats:sec> |
| doi_str_mv | 10.1182/bloodadvances.2019001143 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZGFkdmFuY2VzLjIwMTkwMDExNDM |
| imprint | American Society of Hematology, 2020 |
| imprint_str_mv | American Society of Hematology, 2020 |
| institution | DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15 |
| issn | 2473-9529, 2473-9537 |
| issn_str_mv | 2473-9529, 2473-9537 |
| language | English |
| last_indexed | 2024-03-01T17:55:01.511Z |
| match_str | chou2020americansocietyofhematology2020guidelinesforsicklecelldiseasetransfusionsupport |
| mega_collection | American Society of Hematology (CrossRef) |
| physical | 327-355 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | American Society of Hematology |
| record_format | ai |
| recordtype | ai |
| series | Blood Advances |
| source_id | 49 |
| spelling | Chou, Stella T. Alsawas, Mouaz Fasano, Ross M. Field, Joshua J. Hendrickson, Jeanne E. Howard, Jo Kameka, Michelle Kwiatkowski, Janet L. Pirenne, France Shi, Patricia A. Stowell, Sean R. Thein, Swee Lay Westhoff, Connie M. Wong, Trisha E. Akl, Elie A. 2473-9529 2473-9537 American Society of Hematology Hematology http://dx.doi.org/10.1182/bloodadvances.2019001143 <jats:sec><jats:title>Background:</jats:title><jats:p>Red cell transfusions remain a mainstay of therapy for patients with sickle cell disease (SCD), but pose significant clinical challenges. Guidance for specific indications and administration of transfusion, as well as screening, prevention, and management of alloimmunization, delayed hemolytic transfusion reactions (DHTRs), and iron overload may improve outcomes.</jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p>Our objective was to develop evidence-based guidelines to support patients, clinicians, and other healthcare professionals in their decisions about transfusion support for SCD and the management of transfusion-related complications.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>The American Society of Hematology formed a multidisciplinary panel that was balanced to minimize bias from conflicts of interest and that included a patient representative. The panel prioritized clinical questions and outcomes. The Mayo Clinic Evidence-Based Practice Research Program supported the guideline development process. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to form recommendations, which were subject to public comment.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The panel developed 10 recommendations focused on red cell antigen typing and matching, indications, and mode of administration (simple vs red cell exchange), as well as screening, prevention, and management of alloimmunization, DHTRs, and iron overload.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>The majority of panel recommendations were conditional due to the paucity of direct, high-certainty evidence for outcomes of interest. Research priorities were identified, including prospective studies to understand the role of serologic vs genotypic red cell matching, the mechanism of HTRs resulting from specific alloantigens to inform therapy, the role and timing of regular transfusions during pregnancy for women, and the optimal treatment of transfusional iron overload in SCD.</jats:p></jats:sec> American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support Blood Advances |
| spellingShingle | Chou, Stella T., Alsawas, Mouaz, Fasano, Ross M., Field, Joshua J., Hendrickson, Jeanne E., Howard, Jo, Kameka, Michelle, Kwiatkowski, Janet L., Pirenne, France, Shi, Patricia A., Stowell, Sean R., Thein, Swee Lay, Westhoff, Connie M., Wong, Trisha E., Akl, Elie A., Blood Advances, American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support, Hematology |
| title | American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_full | American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_fullStr | American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_full_unstemmed | American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_short | American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_sort | american society of hematology 2020 guidelines for sickle cell disease: transfusion support |
| title_unstemmed | American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support |
| topic | Hematology |
| url | http://dx.doi.org/10.1182/bloodadvances.2019001143 |